|Assessment process complete
|For the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.
|Rapid review commissioned
|Rapid review completed
|Rapid review outcome
|Full Pharmacoeconomic Evaluation Recommended
|Full submission received from Applicant
|NCPE assessment outcome
|Reimbursement not recommended at the submitted price
The NCPE believe that, at the submitted price, vemurafenib (Zelboraf®) is not cost effective for this indication
The HSE has approved reimbursement following confidential price negotiations.